This process and outcome-oriented evaluation examined the impact that a special funding program for type 1 diabetes research had on the field of type 1 diabetes. (In type 1 diabetes, previously known as juvenile diabetes, the body does not produce insulin, a hormone needed to convert sugar (glucose), starches and other food into energy needed for daily life.) This special funding program administered by the National Institute of Diabetes and Digestive and Kidney Diseases in collaboration with other NIH Institutes and Centers and the Centers for Disease Control and Prevention (CDC). To conduct the evaluation, several metrics were employed, including professional assessment by groups of external experts in type 1 diabetes or related fields; stakeholder input by the program´s grantees; bibliometric analysis to examine the program-supported scientific publications and their impact on the scientific community; and a grant portfolio analysis.
The analysis found that research supported by the special funding program has led to significant scientific advances, yielded robust scientific output (at least 4,755 associated scientific papers that have been cited over 19,000 times in other publications), supported the development of key research resources that are being used by the broad scientific community, and attracted new investigators to pursue research on type 1 diabetes and its complications. Furthermore, the evaluation showed that the special funding program has created a critically important research pipeline that facilitates the identification of new therapies in the laboratory, readies these therapies for testing in people, and provides the infrastructure to support human clinical trials to test these promising therapies. Thus, research supported by the special funding program is directly impacting the health and quality of life of people with type 1 diabetes. Because many of the programs supported by the special funding program are recently established and require long time horizons to complete, external experts evaluating the program anticipate that ever greater benefits to the health of patients will be achieved in the coming years.
Report Title: Evaluation Report on the Special Statutory Funding Program for Type 1 Diabetes Research, http://www.T1Diabetes.nih.gov/evaluation
Agency Sponsor: NIH, National Institutes of Health
Federal Contact: Mary Hanlon, Ph.D., 301-496-6623
Performer: NIH with logistical support from Macro International, Inc.; Atlanta, GA
PIC ID: 8817